Skip to main content

Table 3 Quality measures for patients diagnosed with CRC between 2004 and 2006, and comparisons by geography

From: Does geography influence the treatment and outcomes of colorectal cancer? A population-based analysis

   Geographic variation RHA group
Quality measure Overall (n/N) Winnipeg (n/N) Other (n/N) P value Winnipeg North Manitoba South Manitoba Middle Manitoba P value
  (n/ N) (n/ N) (n/ N) (n/ N)  
Total colonic examination 75.55% 75.08% 76.20% 0.604 75.08% 65.00% 74.00% 81.53% 0.049
(1,230/1,628) (705/939) (525/689) (705/939) (26/40) (296/400) (203/249)
Anastomotic leak/reoperation rate 1.72% 2.17% 1.13% 0.168 2.17% 2.94% 1.34% 0.51% 0.355a
(21/1,220) (15/691) (6/529) (15/691) (1/34) (4/298) (1/197)
Extent of lymphadenectomy          
>12 lymph nodes 68.75% 69.07% 68.31% 0.749 69.07% 58.97% 72.42% 63.22% 0.054
(1,080/1,571) (623/902) (457/669) (623/902) (23/39) (281/388)  
Positive lymph node status 45.47% 45.76% 45.09% 0.790 45.76% 48.72% 43.48% 47.11% 0.781
(719/1,581) (416/909) (303/672) (416/909) (19/39) (170/391) (114/242)
Medical oncology for rectal cancer          
Stage I to IV preoperative consultation 13.15% 12.90% 13.51% 0.866 12.90% 28.57% 13.51% 11.94% 0.668
(48/365) (28/217) (20/148) (28/217) (2/7) (10/74) (8/67)
Stage II/III preoperative consultation 16.25% 14.48% 18.95% 0.359 14.48% 40.00% 22.73% 13.04% 0.250
(39/240) (21/145) (18/95) (21/145) (2/5) (10/44) (6/46)
Stage II/III seen within 8 weeks of major surgery 36.25% 37.24% 34.74% 0.693 37.24% 40.00% 43.18% 26.09% 0.382
(87/240) (54/145) (33/95) (54/145) (2/5) (19/44) (12/46)
Stage II/III seen within 16 weeks of major surgery 63.33% 63.45% 63.16% 0.964 63.45% 60.00% 77.27% 50.00% 0.065
(152/240) (92/145) (60/95) (92/145) (3/5) (34/44) (23/46)
Radiation oncology for rectal cancer          
Stage I to IV preoperative consultation 17.81% 18.43% 16.89% 0.706 18.43% 14.29% 18.92% 14.93% 0.906
(65/365) (40/217) (25/148) (40/217) (1/7) (14/74) (10/67)
Stage II/III preoperative consultation 22.50% 23.45% 21.05% 0.664 23.45% 20.00% 27.27% 15.22% 0.559
(54/240) (34/145) (20/95) (34/145) (1/5) (12/44) (7/46)
Stage II/III seen within 8 weeks of major surgery 31.25% 33.79% 27.37% 0.294 33.79% 0% 27.27% 30.43% 0.384
(75/240) (49/145) (26/95) (49/145) (0/5) (12/44) (14/46)
Stage II/III seen within 16 weeks of major surgery 67.08% 68.28% 65.26% 0.627 68.28% 40.0% 77.27% 56.52% 0.105
(161/240) (99/145) (62/95) (99/145) (2/5) (34/44) (26/46)
Stage III colon cancer seen within 8 weeks of surgery 27.27% 27.35% 27.15% 0.966 27.35% 55.56% 28.92% 20.34% 0.160
(102/374) (61/223) (41/151) (61/223) (5/9) (24/83) (12/59)
Stage III colon cancer seen within 16 weeks of surgery 50.80% 47.09% 56.29% 0.081 47.09% 77.78% 63.86% 42.37% 0.011
(190/374) (105/223) (85/151) (105/223) (7/9) (53/83) (25/59)
30-day mortality 3.75% 4.05% 3.34% 0.506^ 4.05% 2.5% 4.00% 2.41% 0.643^
(61/1,628) (38/939) (23/689) (38/939) (1/40) (16/400) (6/249)
Surveillance colonoscopy within 12 months of surgery 29.62% 30.06% 29.02% 0.674 30.06% 25.00% 31.33% 26.05% 0.535
(410/1,384) (242/805) (168/579) (242/805) (8/32) (104/332) (56/215)
Surveillance colonoscopy within 14 months of surgery 45.37% 47.22% 42.81% 0.106 47.22% 32.26% 45.12% 40.76% 0.167
  (618/1,362) (374/792) (244/570)   (374/792) (10/31) (148/328) (86/211)  
  1. aUsage of Monte-Carlo estimation of exact P value instead of direct P value computations, since the sample size is large and some cell values are less than five; ^death within 30 days compared to death after 30 days and patients who were still alive. CRC colorectal cancer, RHA regional health authority.